Pharmacogenomics and Personalized Medicine (Dec 2023)
Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
Abstract
Priyanka Kolli,1 Grace Kelley,1 Marianela Rosales,2 Justin Faden,1 Ryan Serdenes3 1Department of Psychiatry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; 2Department of Psychiatry and Human Behavior, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 3Department of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USACorrespondence: Ryan Serdenes, Email [email protected]: Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine’s PubMed.gov resource (https://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.Keywords: olanzapine, pharmacokinetics, drug-drug interactions, pharmacodynamics, clinical psychopharmacology
